During the 12th Annual Scientific Sessions (January 29 to February 1, 2009) of the Society for Cardiovascular Magnetic Resonance (SCMR), the world's major international society for cardiovascular imaging, the role of magnetic resonance imaging to assess the effect of therapy in patients with acute myocardial infarction will be demonstrated in a series of papers. Cardiovascular magnetic resonance imaging offers the ability to measure after therapy the size a myocardial infarction would have had if no therapy had been performed (Salvage-imaging). This allows physicians to assess the effect of their intervention and thus, to perform studies to optimize the benefit to their patients.
Before this new technique became available, this knowledge could only be generated to compare large groups of patients who underwent different treatment regimes to average the differences between the groups. With the new technique, these differences can now be corrected for and thus much faster progress towards individually optimized therapy can be
generated.
"Using the new magnetic resonance technique we have been able to show in a relatively small trial of 220 patients, that therapy in patients after myocardial infarction can be optimized adding antioxidative agents to standard therapy," said Holger Thiele, MD, from the University of Leipzig, Germany. "We had known this from animal data before and were now
able to demonstrate this effect in patients using magnetic resonance imaging as an endpoint."
Magnetic resonance imaging has already been established as an endpoint for cardiac function, size and measuring the size of irreversible myocardial damage after myocardial infarction. It is now expanding to a further endpoint for myocardial salvage in patients with acute myocardial infarction.
About the Society for Cardiovascular Magnetic Resonance (SCMR)
Founded in 1994, SCMR is a professional association whose vision is to be the recognized representative and advocate for physicians, scientists and technologists who work in the field of cardiovascular magnetic resonance. SCMR endeavors to be the principal international, independent organization committed to the further development of cardiovascular magnetic resonance through education, quality control, research, and training. For more information, visit www.scmr.org.
Business & Industry
- BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson's disease
- European Commission approves Pfizer's RSV vaccine ABRYSVO® to help protect adults aged 18-59 against RSV lower respiratory tract disease
- Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor
- AstraZeneca enters license agreement with Alteogen
- Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma
Research & Development
- Scientists finally confirm vitamin B1 hypothesis from 1958
- Empowering antibodies to better activate the immune system
- Existing drug has potential for immune paralysis
- Study finds pinworm medication has potential to treat aggressive skin cancer
- Scientists achieve record-breaking growth in miniature, functional liver models
- Popular diabetes medications, including GLP-1 drugs, may protect against Alzheimer's disease
- Potential treatment for Parkinson's using investigational cell therapy shows early promise
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy